Opioid Use Disorder (OUD) remains a critical concern, especially with the surge of potent opioids like fentanyl.
A study, published in JAMA Network Open, unveils crucial insights about the efficacy of different doses of buprenorphine, a medication used in OUD treatment, and suggests a need to reassess current dosing recommendations.
Researchers analyzed the treatment records of patients prescribed buprenorphine in Rhode Island from 2016 to 2020, focusing on the relationship between the dosage of buprenorphine and treatment discontinuation.
The study comprised 6,499 patients, predominantly males aged between 25 and 44 years, initiating buprenorphine treatment for OUD during the period when fentanyl, a potent opioid, was increasingly associated with overdoses and deaths.
The study revealed that patients receiving a lower dose of buprenorphine (16 mg, the recommended target daily dose by the FDA) were 20% more likely to discontinue treatment within 180 days compared to those on a higher dose (24 mg).
59% of those on 16 mg and 53% of those on 24 mg discontinued treatment within this period.
This finding raises crucial questions about the adequacy of the existing dosing guidelines, established before the rise of fentanyl in the drug market.
The current guideline-recommended dose might be insufficient to retain individuals in treatment effectively, especially those with higher levels of opioid tolerance and dependence due to exposure to substances like fentanyl.
Buprenorphine is recognized as a life-saving medication for OUD, mitigating opioid cravings and withdrawal symptoms, thus aiding in reducing opioid use, overdose risks, and promoting recovery.
However, the efficacy of this medication is significantly contingent on the appropriate dosing and treatment retention.
Given the prevalent opioid crisis intensified by fentanyl, it is imperative to reevaluate and potentially revise the buprenorphine dosing guidelines to optimize treatment outcomes and accommodate the changing landscape of opioid use.
Higher doses of buprenorphine may be pivotal in improving treatment retention and addressing the increased opioid tolerance in individuals exposed to potent opioids.
Researchers plan to extend their study through a clinical trial to evaluate the impacts of buprenorphine doses up to 24 mg on treatment retention, overdose risks, and mortality.
The trial will also explore other determinants of treatment retention, including clinician prescribing practices and diverse patient-related factors.
The insights from future studies can substantially contribute to updating and enhancing the standards of OUD treatment, aligning them more closely with the realities of the current opioid crisis.
The emergence and predominance of potent opioids necessitate an urgent reevaluation of existing treatment protocols for opioid use disorders.
This study underscores the possibility that higher buprenorphine doses may be more efficacious in retaining patients in treatment, potentially reducing the risk of overdose and death.
It acts as a precursor to further research and potential modifications in treatment guidelines, aiming for a more responsive and effective approach to the evolving challenges in opioid use disorders.
If you care about pain, please read studies about how to manage your back pain, and exercise harder if you want to ward off pain due to ageing.
For more information about pain, please see recent studies about how to live pain-free with arthritis, and results showing common native American plant may help reduce diarrhea and pain.
The research findings can be found in JAMA Network Open.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
